A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

Current Medical Research and Opinion

Volumn 21, Issue 4, 2005, Pages 631-641

  Wade, Alan G ^a   Toumi, Idris ^b   Hemels, Michiel E H ^b  

^a CPS Research   (United Kingdom)

^b Lundbeck   (France)

Author keywords

Cost effectiveness; Depression; Escitalopram, cost of; UK

Indexed keywords

CITALOPRAM; ESCITALOPRAM; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG COST; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 18744369956     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X41462     Document Type: Article

References (39)

1. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000;1:3-10
2. Hale AS. ABC of mental health: depression. Br Med J 1997;315:43-6
3. Angst J. The epidemiology of depressive disorders. Eur Neuropsychopharmacol 1995;5:95-8
4. Scott AIF, Freeman CPL. Edinburgh primary care depression study: treatment, outcome, patient satisfaction and cost after 16 weeks. Br Med J 1992;304:883-7
5. Thompson D, Richardson E. Current issues in the economics of depression management. Curr Psychiatry Rep 1999;1: 125-34
6. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004;20:869-78
7. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004;38:45-55
8. Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004;30:158-66
9. Culpepper L. Escitalopram: a new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry 2002;4:209-14
10. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004;19:305-10
11. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211-7
12. Lepola UM, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004;19:149-55
13. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002;5:91-107
14. François C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003;4:12-9
15. NHS National Institute for Clinical Excellence. Guidance for manufacturers and sponsors. Technology appraisals process series No 5. Available at: Http://www.nice.org.uk [accessed: 04/05/2004]
16. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for psychopharmacology guidelines. J Psychopharmacol 2000;14:3-20
17. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8
18. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl 1):29-35
19. General Practice Research Database. GPRD analysis. Data on file H. Lunbeck A/S Paris; 2003
20. Expert panel. Depression referrals to secondary care - treatment algorithm development. Cam Market Research. Data on file H. Lundbeck A/S Paris; 2002
21. Data Archive. OPCS surveys of psychiatric morbidity: private household survey. Colchester, Essex; 1993
22. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97-111
23. Leff J, Vearnals S, Brewin CR, et al. The London Depression Intervention Trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. Br J Psychiatry 2000;177:95-100
24. Department of Health. Hospital episode statistics 1999-2000. Available at http://www.nepho.org.uk [accessed: 07/06/2004]
25. Meltzer H, Gill B, Petticrew M, Hinds K. OPCS surveys of psychiatric morbidity in Great Britain. Report 3: economic activity and social functioning of adults with psychiatric disorders. London: OPCS; 1995
26. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001;4:113-8
27. O'Donoghue J, Goulding L, Allen G. Consumer price inflation since 1750. Economic trends (Report No. 604). National Office for Statistics; 2004
28. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. Canterbury: University of Kent; 2001
29. Casciano J, Doyle J, Arikian S, Casciano R. The health economic impact of antidepressant usage from a payer's perspective: a multinational study. Int J Clin Pract 2001;55:292-9
30. Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16-31
31. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000;18:143-8
32. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-73
33. Lenox-Smith A, Conway P, Knight C. Cost-effectiveness of representatives of three classes of antidepressants used in major depressive disorder in the UK. Pharmacoeconomics 2004; 22:311-9
34. Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996;168:768-71
35. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9
36. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in patients in primary care with major depressive disorder. Neuropsychobiology 2004;50:57-6
37. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001;62:135-42
38. National Health Service England and Wales. Drug Tariff Q4 2003. London: Prescription Pricing Authority; 2004
39. Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000;15:378-87